Literature DB >> 24081111

High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.

Masayuki Yamakura1, Kenji Tsuda, Tomotaka Ugai, Hiroki Sugihara, Yuki Nisihida, Masami Takeuchi, Kosei Matsue.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24081111     DOI： 10.1159/000353126

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  3 in total

1.  Activating transcription factor 4 underlies the pathogenesis of arsenic trioxide-mediated impairment of macrophage innate immune functions.

Authors:  Ritesh K Srivastava; Changzhao Li; Yong Wang; Zhiping Weng; Craig A Elmets; Kevin S Harrod; Jessy S Deshane; Mohammad Athar
Journal:  Toxicol Appl Pharmacol       Date:  2016-07-25       Impact factor: 4.219

2.  Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy.

Authors:  Jacob L Glass; Andriy Derkach; Patrick Hilden; Amber King; Susan K Seo; Katya Ahr; Ashwin Kishtagari; Ross L Levine; Martin S Tallman; Dan Douer
Journal:  Leuk Res       Date:  2021-03-31       Impact factor: 3.715

Review 3.  Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Authors:  Liang-Kung Chen; Hidenori Arai; Liang-Yu Chen; Ming-Yueh Chou; Samsuridjal Djauzi; Birong Dong; Taro Kojima; Ki Tae Kwon; Hoe Nam Leong; Edward M F Leung; Chih-Kuang Liang; Xiaohong Liu; Dilip Mathai; Jiun Yit Pan; Li-Ning Peng; Eduardo Rommel S Poblete; Philip J H Poi; Stewart Reid; Terapong Tantawichien; Chang Won Won
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.